Beyond Equity: When Should Life Sciences Companies Consider Convertible Debt?

Beyond Equity: When Should Life Sciences Companies Consider Convertible Debt?

Webinar
Webinar CLE

On December 14, partners Craig Hilts, Erika Robinson and Dino Wu, alongside J. Wood Capital Advisors Founder & CEO Jason Wood and Managing Director Alton Lo, will present an overview of convertible debt transactions, dilution protection mechanisms and recent market trends in the life sciences industry.

As life sciences companies mature and advance towards commercialization of a product, they often consider issuing a convertible bond as a means of raising less dilutive capital. Current market conditions are very strong for issuers and companies have been able to raise capital at attractive pricing. Panelists will provide guidance to life sciences companies who may be considering whether and when a convertible bond financing might be appropriate and will discuss keys for successfully structuring and executing a convertible bond financing.

During the webinar, participants will have the opportunity to contribute questions online. CLE credit will be offered.

View the webinar recording.*

*CLE credit is not available for those who watch webinar recordings.

 

Read More About the Event

Speakers